Perspective Therapeutics Q1 EPS Increased by HC Wainwright

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for Perspective Therapeutics in a report released on Monday, March 23rd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.30) per share for the quarter, up from their prior estimate of ($0.38). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($1.06) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The company had revenue of $0.04 million during the quarter.

Other equities research analysts have also recently issued reports about the stock. BTIG Research restated a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Piper Sandler assumed coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 18th. UBS Group raised their price target on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Finally, B. Riley Financial lifted their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $12.63.

Perspective Therapeutics Trading Down 6.6%

Shares of CATX stock opened at $4.22 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.17 and a quick ratio of 5.17. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.16. The company’s 50-day moving average price is $4.52 and its 200-day moving average price is $3.47.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares during the period. Deutsche Bank AG boosted its stake in shares of Perspective Therapeutics by 6.1% in the fourth quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after purchasing an additional 3,119 shares during the period. Vontobel Holding Ltd. boosted its stake in shares of Perspective Therapeutics by 25.0% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock valued at $69,000 after purchasing an additional 5,000 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares in the last quarter. Finally, Taylor & Morgan Wealth Management LLC grew its holdings in shares of Perspective Therapeutics by 6.6% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock valued at $267,000 after purchasing an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.